Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Significance of Circulating Tumor DNA in Hodgkin Lymphoma

NCT06263530 is registered in ClinicalTrials.gov with Interni hematologicka klinika FNKV as lead sponsor.

NCT NCT06263530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06263530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Significance of Circulating Tumor DNA in Hodgkin Lymphoma
Lead sponsor
Interni hematologicka klinika FNKV
Phase
Observational
Overall status
Recruiting
Start date
January 2, 2022
Completion date
December 31, 2027
Enrollment
500 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

prognostic cancer model